Daily Stock Analysis, MYOK, MyoKardia Inc, priceseries

MyoKardia Inc. Daily Stock Analysis
Stock Information
Open
224.82
Close
224.91
High
225.00
Low
224.52
Previous Close
224.80
Daily Price Gain
0.11
YTD High
225.00
YTD High Date
Nov 16, 2020
YTD Low
6.24
YTD Low Date
Feb 11, 2016
YTD Price Change
214.38
YTD Gain
2035.90%
52 Week High
225.00
52 Week High Date
Nov 16, 2020
52 Week Low
6.24
52 Week Low Date
Feb 11, 2016
52 Week Price Change
214.38
52 Week Gain
2035.90%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 1. 2017
11.95
Feb 2. 2017
12.96
1 Trading Days
8.45%
Link
LONG
Jul 24. 2017
14.20
Sep 5. 2017
41.94
30 Trading Days
195.33%
Link
LONG
Dec 19. 2017
38.75
Jan 8. 2018
41.78
12 Trading Days
7.81%
Link
LONG
Jan 9. 2018
47.55
Jan 24. 2018
51.71
10 Trading Days
8.74%
Link
LONG
Feb 14. 2018
53.85
Mar 6. 2018
58.57
13 Trading Days
8.76%
Link
LONG
Jun 28. 2018
49.05
Jul 27. 2018
55.84
20 Trading Days
13.84%
Link
LONG
Feb 14. 2019
42.00
Mar 25. 2019
52.33
26 Trading Days
24.59%
Link
LONG
Nov 19. 2019
56.18
Dec 12. 2019
64.56
16 Trading Days
14.92%
Link
LONG
Apr 16. 2020
56.27
May 1. 2020
60.72
11 Trading Days
7.90%
Link
Company Information
Stock Symbol
MYOK
Exchange
NasdaqGS
Company URL
http://www.myokardia.com
Company Phone
650-741-0900
CEO
Anastasios E. Gianakakos
Headquarters
California
Business Address
333 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001552451
About

MyoKardia, Inc. operates as a biopharmaceutical company which engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.

Description

Clinical-stage biotech developing therapies for heritable cardiomyopathies.